Yuhan Corporation, a significant player in the Healthcare sector, currently holds a market capitalization of 5.42 Trillion. The company operates within the Drug Manufacturers industry. Given its recent market performance, which includes a 2.65% decline over the past week, our technical analysis aims to provide a clear, data-driven outlook for potential traders.

The technical indicators for Yuhan Corporation result in a total score of -4, leading to a "Strong Sell" rating. This assessment is primarily driven by a strong long-term bearish trend, as the current price of KRW73,600.00 is well below its 200-day simple moving average (KRW90,695.43), contributing a heavily weighted score of -2. Further confirming this negative outlook, the MACD histogram is negative, indicating bearish momentum (Score: -1). Additionally, the On-Balance Volume (OBV) is below its moving average, suggesting distribution pressure as volume is higher on down days (Score: -1). The RSI at 38.32 is in neutral territory, while the ADX at 17.34 indicates the current trend lacks strong momentum, both yielding a score of 0.

In conclusion, the strong bearish technical signals align with a lack of compelling fundamental data. Key metrics such as the P/E ratio and the last reported EPS are currently unavailable, making a fundamental valuation challenging. The next earnings date has also not been announced. While a dividend yield of 80.0 is noted, this figure is exceptionally high and may warrant further investigation by investors for potential data inaccuracies or special circumstances. Without positive earnings surprises or fundamental strengths to offset the technical weakness, the evidence strongly supports a cautious, bearish stance on Yuhan Corporation.